Based on current population trends, the researchers predict that MCC incidence will grow to more than 3,200 in 2025 from nearly 2,500 cases

Photo credit: Fred Hutch News Service Intratumoural infiltration by Merkel cell polyomavirus (MCPyV) specific T-cells has been associated with significantly improved Merkel cell carcinoma (MCC) survival. That suggests augmenting the number or avidity of virus-specific T-cells may have therapeutic benefit, according to findings published in Cancer Immunology (Jan. 16, 2017; 5(2):1–11). In this study, investigators from the University of Washington and the Fred Hutchinson Cance

A new immune system marker test may allow patients who have been successfully treated for Merkel cell carcinoma (MCC) to be stratified by risk of recurrence and potentially allow any recurrence to be detected earlier, researchers report online in the journal Cancer (Dec. 7, 2016). The new test measures the presence of an antibody to a cancer-driving protein produced by a virus that causes MCC, according to a press release from the Fred Hutchinson Cancer Research Center in Sea